Javitt Jonathan C
- SEC CIK
- 0001303782
No open-market purchases or sales filed in the past year.
Current role at each company
- NRXP NRX Pharmaceuticals, Inc.Chairman and Chief Scientistas of Sep 10, 2025
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Javitt Jonathan C as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 18, 2024 (view filing) | Dec 17 | 1 day | Javitt Jonathan CChairman and Chief Scientist | PPurchase | +40.0K | $1.17 | +$46.8K | +89.6%84.6K after | |
| Aug 24, 2023 (view filing)12:14 PM ET | Aug 23 | 1 day | Javitt Jonathan CChief Scientist | PPurchase | +100.0K | $0.33 | +$33.0K | +28.9%446.3K after | |
| Aug 23, 2023 (view filing)9:24 AM ET | Aug 22 | 1 day | Javitt Jonathan CChief Scientist | PPurchase | +200.0K | $0.322 | +$64.4K | +136.7%346.3K after | |
| Dec 9, 2022 (view filing) | Dec 7 | 2 days | Javitt Jonathan CDirector, 10% Owner | SSaleCommon Stock, par value $0.001 per share | −400.0K | $1.00 | −$400.0K | −3.0%12.9M after | |
| Jun 2, 2022 (view filing) | Jun 1 | 1 day | Javitt Jonathan CChief Scientist | PPurchase | +100.0K | $0.58 | +$58.0K | +215.8%146.3K after | Amended |